- Home
- SEMR vs ETNB Comparison
SEMR vs ETNB Comparison
Compare SEMR & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEMR
- ETNB
- Stock Information
- Founded
- SEMR 2008
- ETNB 2018
- Country
- SEMR United States
- ETNB United States
- Employees
- SEMR N/A
- ETNB N/A
- Industry
- SEMR EDP Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- SEMR Technology
- ETNB Health Care
- Exchange
- SEMR Nasdaq
- ETNB Nasdaq
- Market Cap
- SEMR 1.3B
- ETNB 1.5B
- IPO Year
- SEMR 2021
- ETNB 2019
- Fundamental
- Price
- SEMR $9.41
- ETNB $9.53
- Analyst Decision
- SEMR Buy
- ETNB Strong Buy
- Analyst Count
- SEMR 8
- ETNB 8
- Target Price
- SEMR $17.00
- ETNB $26.43
- AVG Volume (30 Days)
- SEMR 798.5K
- ETNB 1.3M
- Earning Date
- SEMR 08-04-2025
- ETNB 08-08-2025
- Dividend Yield
- SEMR N/A
- ETNB N/A
- EPS Growth
- SEMR N/A
- ETNB N/A
- EPS
- SEMR 0.05
- ETNB N/A
- Revenue
- SEMR $396,021,000.00
- ETNB N/A
- Revenue This Year
- SEMR $21.85
- ETNB N/A
- Revenue Next Year
- SEMR $18.50
- ETNB N/A
- P/E Ratio
- SEMR $198.37
- ETNB N/A
- Revenue Growth
- SEMR 22.75
- ETNB N/A
- 52 Week Low
- SEMR $7.90
- ETNB $4.16
- 52 Week High
- SEMR $18.74
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- SEMR 51.03
- ETNB 42.40
- Support Level
- SEMR $8.60
- ETNB $9.12
- Resistance Level
- SEMR $10.00
- ETNB $10.48
- Average True Range (ATR)
- SEMR 0.32
- ETNB 0.47
- MACD
- SEMR 0.09
- ETNB -0.16
- Stochastic Oscillator
- SEMR 57.14
- ETNB 17.90
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).